Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to outsmart resistant prostate cancer

NCT ID NCT06705686

Recruiting now Disease control Sponsor: TechnoGenesys, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new oral drug called (R)-9bMS in about 18-30 men with metastatic castration-resistant prostate cancer, a form of prostate cancer that has stopped responding to hormone therapy. The drug works by blocking a protein called ACK1, which may help shrink tumors and boost the immune system's ability to fight cancer. The main goal is to check the drug's safety and find the best dose for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
(R)-9bMS (also called Mahatinib), a new targeted drug taken by mouth
What this could lead to
If this early trial shows the drug is safe and has anti-tumor activity, it could point toward a new treatment option for men with advanced prostate cancer that has stopped responding to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 18-30 participants, so the main goal is safety, not effectiveness. The drug may not work well in humans or may cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC) METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA

Contacts and locations

Locations

  • University of Wisconsin Carbone Cancer Center (UWCCC) - Cancer Connect

    RECRUITING

    Madison, Wisconsin, 53792, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.